{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-26-000097","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-07-23T11:14:59+00:00","discovered_at":"2026-07-23T11:20:00.318688+00:00","generated_at":"2026-07-23T11:20:10.069144+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"West Pharma Q2 net sales up 13.8%, adjusted EPS $2.37 (+28.8%); raises full-year guidance","bullets":["Q2 net sales $872.3M (+13.8% reported, +12.7% organic); adjusted-diluted EPS $2.37 (+28.8%).","Full-year 2026 net sales guidance raised to $3.345B-$3.380B; adjusted EPS guidance raised to $8.85-$9.05.","HVP Components net sales $424.1M (+19.4%); HVP Delivery Devices $131.2M (+29.6%) driven by Biologics and GLP-1 elastomers.","Q3 2026 guidance: net sales $820M-$835M, adjusted EPS $2.14-$2.24.","Repurchased 1.8M shares for $454.3M in H1 2026; declared Q3 dividend $0.22/share."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000097","json":"https://secwatch.observer/filing/0000105770-26-000097.json","markdown":"https://secwatch.observer/filing/0000105770-26-000097.md","text":"https://secwatch.observer/filing/0000105770-26-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/0000105770-26-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/wst-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T11:20:10.069144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}